StockData
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. (JBIO) company profile

JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$15.40+0.06 (+0.42%)

Close on Nov 17, 2026Market cap $979.40MP/E –Yield –

About Jade Biosciences

Pharmaceutical Preparations, SIC 2834

Jade Biosciences is a clinical-stage biopharmaceutical company that discovers and develops biologic therapies to treat autoimmune disorders. The company focuses on monoclonal antibody candidates engineered to improve potency and pharmacokinetic properties over existing alternatives. Its lead product candidate, JADE101, targets a cytokine called APRIL to treat IgA nephropathy, a progressive kidney disease. Its second product candidate, JADE201, targets the BAFF receptor through cellular cytotoxicity and signaling pathway inhibition to address conditions such as rheumatoid arthritis. A third development program, JADE301, targets an undisclosed biological pathway. The company directs its investigational therapies toward patients suffering from serious autoimmune conditions.

The company maintains its corporate headquarters in Waltham, Massachusetts. Its geographic presence includes clinical trial activity in New Zealand, where it evaluates healthy volunteers, alongside laboratory-stage research and development. Additionally, the company collaborates with external biotechnology partners for discovery and preclinical research services.

Summary of the business section of Jade Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Jade Biosciences, Inc.
Headquarters
Waltham, MA
Address
221 Crescent St., Building 23, Suite 105 02453
Phone
(781) 312-3013
Employees
55, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
JBIO
Former tickers
AVTE until Apr 29, 2025
Exchange
Nasdaq
IPO date
Jun 30, 2021
Shares outstanding
64M, Aug 3, 2026
Public float
$289.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-35 reverse, Apr 29, 2025
SEC CIK
1798749
CUSIP
008064206
ISIN
US0080642061
FIGI
BBG00WGHZFH4
Share class FIGI
BBG00WGHZFJ2
EIN
83-1377888

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Tom FrohlichChief Executive Officer, Director86,331
Elizabeth BaltaSee Remarks28,125
Bradford D. DahmsChief Financial Officer37,813
Andrew James KingSee Remarks386,113
Hetal KocinskyChief Medical Officer–
Jonathan QuickSee Remarks–
Mark EisnerDirector–
Eric DobmeierDirector–
Erin LavelleDirector–
Healthcare Co-Invest IV L.P. FairmountDirector–
Healthcare Fund II L.P. FairmountDirector4,553,494
Tomas KiselakDirector–
Funds Management LLC FairmountDirector–
Peter Evan HarwinDirector–
Lawrence Otto KleinDirector86,215
Christopher W. CainDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Tom Frohlich
Chief Executive Officer, President and Director
$621.97K$8.78M$397.91K–$9.80M+618%
Andrew King, Ph.D.
President, Research and Development
$507.30K$3.78M$258.60K–$4.54M+504%
Bradford Dahms
Chief Financial Officer
$233.01K$3.78M$113.60K$3.44K$4.13M–
Timothy P. Noyes
Former Chief Executive Officer
$213.77K––$1.60M$1.81M-46%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 30, 2021
Offer price
$14.00
Securities offered
8,682,142
Gross proceeds
$121.55M
Exchange
Nasdaq
First trading day
Jun 30, 2021
First-day close
$22.83+63.1%
Lock-up ends (est.)
Dec 27, 2021

“The initial public offering price is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 55 full-time employees, 15 of whom have Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?